Testing a targeted drug to eliminate remaining leukemia cells

This trial is testing a medication called gemtuzumab ozogamicin to help patients with acute myeloid leukemia who have had an initial good response to chemotherapy but still have small amounts of leukemia cells remaining. The medication is designed to target and attack these remaining cancer cells. Researchers want to see if this approach can help prevent the leukemia from coming back.

Even when patients respond well to initial chemotherapy, tiny amounts of leukemia cells can sometimes remain and eventually cause the disease to return. This trial is exploring whether this medication might help eliminate those remaining cells and improve long-term survival.